Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Evaluating pupil response to light in patients with retinal conditions

Official title: Objective Perimetry in Normal Subjects,Glaucoma Patients and Retinal Dystrophy Patients

Run by Sheba Medical Center · NCT02014389 · Data updated 2026-11-12

This study is testing a new way to check vision by measuring how pupils respond to light in people with retinal conditions like glaucoma to see if it’s better than current methods.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment200 (estimated)
SponsorSheba Medical Center
Government
Locations1 site (Tel HaShomer)
StatusRecruiting
StartedDecember 1, 2013
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedApril 25, 2024
Trial IDNCT02014389 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18-80 with retinal dystrophies or glaucoma who can provide informed consent.

Probably not a fit

Patients with conditions affecting the pupillary reflex or recent ocular surgeries may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the effectiveness of objective perimetry using a chromatic multifocal pupillometer to monitor visual field defects in patients with retinal dystrophies and glaucoma. The study will measure the pupil light reflex (PLR) in response to short and long wavelength light stimuli across 76 points in the visual field. By comparing the PLR of affected patients to that of healthy participants, the study seeks to establish a more accurate method for detecting visual field defects than traditional subjective perimetry.

Why it matters

Potential benefit: If successful, this study could lead to improved monitoring and management of visual field defects in patients with retinal dystrophies and glaucoma.

How similar studies have gone: Other studies have shown promise in using objective measures for assessing visual field defects, suggesting this approach may be effective.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18-80 years old.
* Signing informed consent.
* Pupillary reflex to light.

Exclusion Criteria:

1. Cloudy corneas.
2. Surgical intraocular ophthalmic procedure within the past 30 days.
3. No reactive pupils.
4. Synechia of the iris to the lens after surgery or inflammation.
5. Neovascularization.
6. Axenfeld-Rieger Syndrome.
7. Iris atrophy (ICE syndrome).
8. Iris coloboma.
9. Sphincter damage due to ischemia.
10. Sphincter damage due to trauma (tears of sphincter or diffuse damage to muscle).
11. Sphincter damage due to Herpes Zoster Uveitis.
12. Sphincter damage due to high intraocular pressure.
13. Iris tumor or cyst.
14. Ectropion uvae.
15. Adie's pupil.
16. Third nerve aberrant regeneration of the iris sphincter.
17. RP patients with Optic neuropathy with the potential of producing a positive RAPD (Relative Afferent Pupillary Defect).
18. Chronic use of myotics or mydriatics.
19. Systemic medication that have affect on pupillary reflex .
20. Any condition preventing accurate measurement or examination of the pupil.

Where it's running

  • Sheba Medical Center
    Tel HaShomer, Israel
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Functional visual field and navigation testing for moderate-to-profound inherited retinal disease

    This project will test whether functional visual field and navigation tests can measure real-world vision and mobility in people with moderate-to-profound inherited retinal diseases.

    Recruiting Ray Therapeutics, Inc. · Irvine, California · NCT07502664

  • Assessing vision measurement methods for patients with retinal degeneration

    This study is testing different ways to measure vision in people with retinal degeneration to see how their eyesight affects daily life and how it changes over time.

    Recruiting Ray Therapeutics, Inc. · Irvine, California · NCT06375239

  • Disulfiram (Antabuse) for vision in retinal degeneration

    This study will test whether taking oral disulfiram (Antabuse) improves vision in adults with retinal degeneration who are also being treated for alcohol use disorder.

    Recruiting Phase 1 University of Rochester · Rochester, New York · NCT06319872

  • Advanced imaging techniques for eye conditions

    This study is testing new advanced imaging techniques to see if they can help doctors better understand and diagnose eye diseases like retinitis pigmentosa and maculopathy.

    Recruiting Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · Paris · NCT04129021

  • Using stem cells to treat retinal and optic nerve damage

    This study is testing if using stem cells from your own bone marrow can help improve vision in people with serious eye damage from conditions like age-related macular degeneration and optic nerve problems.

    Recruiting at 4 sites MD Stem Cells · Westport, Connecticut and 3 other locations · NCT03011541

  • Balance training for people with glaucoma

    A randomized study tests whether a structured eight-week balance program helps adults with glaucoma improve balance, reduce fall risk, and lessen fear of falling.

    Recruiting Kanuni Sultan Suleyman Training and Research Hospital · Küçükçekmece, Istanbul · NCT07910955

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.